

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
10 February 2022 (10.02.2022)



(10) International Publication Number
WO 2022/031894 A1

(51) International Patent Classification:

A61K 31/675 (2006.01) *A61P 31/18* (2006.01)
A61K 45/06 (2006.01) *C07F 9/6561* (2006.01)
A61P 31/12 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2021/044615

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:

05 August 2021 (05.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

Published:

- with international search report (Art. 21(3))

(30) Priority Data:

63/062,899 07 August 2020 (07.08.2020) US

(71) Applicant: **GILEAD SCIENCES, INC.** [US/US]; 333
Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: **BYUN, Daniel H.**; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).
CHUN, Byoung-Kwon; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US).
CLARKE, Michael O.; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US).
JANSA, Petr; c/o Gilead Sciences, Inc., 333 Lakeside Drive,
Foster City, California 94404 (US). **NADUTHAMBI,**
Devan; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster
City, California 94404 (US). **SQUIRES, Neil H.**; 627
Taylor Street, Apt. 43, San Francisco, California 94102
(US).

(74) Agent: **SIMPSON, Alexis N.** et al.; Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE

(57) Abstract: Compounds, compositions, and method useful for treating a viral infection, such as human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, are disclosed. In particular, prodrugs of phosphonamide nucleotide analogues and methods for their preparation and use as therapeutic or prophylactic agents are disclosed.



WO 2022/031894 A1